Characteristics of 9194 Patients With Left Ventricular Hypertrophy: The LIFE Study
Losartan was the first available orally administered selective antagonist of the angiotensin II type 1 receptor developed for the treatment of hypertension. The Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study is a double-blind, prospective, parallel group study designed to...
Gespeichert in:
| Veröffentlicht in: | Hypertension (Dallas, Tex. 1979) Tex. 1979), 1998-12, Vol.32 (6), p.989-997 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 997 |
|---|---|
| container_issue | 6 |
| container_start_page | 989 |
| container_title | Hypertension (Dallas, Tex. 1979) |
| container_volume | 32 |
| creator | Dahlof, Bjorn Devereux, Richard B Julius, Stevo Kjeldsen, Sverre E Beevers, Gareth de Faire, Ulf Fyhrquist, Frej Hedner, Thomas Ibsen, Hans Kristianson, Krister Lederballe-Pedersen, Ole Lindholm, Lars H Nieminen, Markku S Omvik, Per Oparil, Suzanne Wedel, Hans |
| description | Losartan was the first available orally administered selective antagonist of the angiotensin II type 1 receptor developed for the treatment of hypertension. The Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study is a double-blind, prospective, parallel group study designed to compare the effects of losartan with those of the beta-blocker atenolol on the reduction of cardiovascular morbidity and mortality. Patients with essential hypertension, aged between 55 and 80 years, and ECG-documented left ventricular hypertrophy (LVH) were included. Altogether, 9223 patients in Scandinavia, the United Kingdom, and the United States were randomized from June 1995 through April 1997, and 9194 remain after exclusion of a study center at which irregularities were discovered. This population of hypertensives (mean systolic/diastolic blood pressure, 174.4/97.8 mm Hg) with LVH comprises women (54.1%) and men, mostly retired from active work (mean age, 66.9 years), with a high prevalence of overweight (mean body mass index, 28.0 kg/m), diabetes mellitus (12.3%), lipid disorders (18.0%), and symptoms or signs of coronary heart disease (15.1%). There were fewer current smokers ( |
| doi_str_mv | 10.1161/01.HYP.32.6.989 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_432834</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>37618734</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3737-95ebe80ebd510a4a12c8c2a110b3139b98f6a8b2e568b76dc62e82981f34b5763</originalsourceid><addsrcrecordid>eNpFkE1r3DAQhkVoIdu051xF6NWORpJlKbewJN3AQkObfuQkZO0YO3HWriSz7L-vll3aucwHz7wzvIRcAisBFFwzKFfPj6XgpSqNNmdkARWXhayUeEcWDIwsDMDvc_IhxhfGQEpZL8i3ZeeC8wlDH1PvIx1bajJLH13qcZsi_dWnjq6xTfRn7kPv58EFutpPGFIYp25_Q586pOuH-zv6Pc2b_UfyvnVDxE-nfEF-3N89LVfF-uuXh-XtuvCiFnVhKmxQM2w2FTAnHXCvPXcArBEgTGN0q5xuOFZKN7XaeMVRc6OhFbKpaiUuSHHUjTuc5sZOoX9zYW9H19vT6DVXaKXgWsjMXx35KYx_ZozJvoxz2OYXLWcV1xVXOkPXR8iHMcaA7T9ZYPbgs2Vgs89WcKts9jlvfD7Juujd0Aa39X38v6bq_PPhujxiu3HIbsfXYd5hsB26IXWW5ZD5fgEm0zx3xWFUi7_CtYu8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>205285268</pqid></control><display><type>article</type><title>Characteristics of 9194 Patients With Left Ventricular Hypertrophy: The LIFE Study</title><source>EZB Electronic Journals Library</source><source>American Heart Association</source><source>Journals@Ovid Complete</source><creator>Dahlof, Bjorn ; Devereux, Richard B ; Julius, Stevo ; Kjeldsen, Sverre E ; Beevers, Gareth ; de Faire, Ulf ; Fyhrquist, Frej ; Hedner, Thomas ; Ibsen, Hans ; Kristianson, Krister ; Lederballe-Pedersen, Ole ; Lindholm, Lars H ; Nieminen, Markku S ; Omvik, Per ; Oparil, Suzanne ; Wedel, Hans</creator><creatorcontrib>Dahlof, Bjorn ; Devereux, Richard B ; Julius, Stevo ; Kjeldsen, Sverre E ; Beevers, Gareth ; de Faire, Ulf ; Fyhrquist, Frej ; Hedner, Thomas ; Ibsen, Hans ; Kristianson, Krister ; Lederballe-Pedersen, Ole ; Lindholm, Lars H ; Nieminen, Markku S ; Omvik, Per ; Oparil, Suzanne ; Wedel, Hans</creatorcontrib><description>Losartan was the first available orally administered selective antagonist of the angiotensin II type 1 receptor developed for the treatment of hypertension. The Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study is a double-blind, prospective, parallel group study designed to compare the effects of losartan with those of the beta-blocker atenolol on the reduction of cardiovascular morbidity and mortality. Patients with essential hypertension, aged between 55 and 80 years, and ECG-documented left ventricular hypertrophy (LVH) were included. Altogether, 9223 patients in Scandinavia, the United Kingdom, and the United States were randomized from June 1995 through April 1997, and 9194 remain after exclusion of a study center at which irregularities were discovered. This population of hypertensives (mean systolic/diastolic blood pressure, 174.4/97.8 mm Hg) with LVH comprises women (54.1%) and men, mostly retired from active work (mean age, 66.9 years), with a high prevalence of overweight (mean body mass index, 28.0 kg/m), diabetes mellitus (12.3%), lipid disorders (18.0%), and symptoms or signs of coronary heart disease (15.1%). There were fewer current smokers (<17%) than in the general population, and [almost equal to]7% were nonwhite. Almost 30% of participants had been untreated for at least 6 months when screened for the study. Only 1557 persons who entered the placebo run-in period of 14 days were excluded, predominantly because of sitting blood pressures above or below the predetermined range of 160-200/95-115 mm Hg and ECG-LVH criteria not met. By application of simple 12-lead ECG criteria for LVH (Cornell voltage QRS duration product formula plus Sokolow-Lyon voltage read by a core laboratory), hypertensive patients with LVH with an average 5-year coronary heart disease risk of 22.3% according to the Framingham score were identified. This population is now being treated (goal, <140/90 mm Hg) in adherence with the protocol for at least 4 years after final enrollment (ie, through April 2001) and until at least 1040 patients suffer myocardial infarction, stroke, or cardiovascular death. (Hypertension. 1998;32:989-997.)</description><identifier>ISSN: 0194-911X</identifier><identifier>EISSN: 1524-4563</identifier><identifier>DOI: 10.1161/01.HYP.32.6.989</identifier><identifier>CODEN: HPRTDN</identifier><language>eng</language><publisher>Philadelphia, PA: American Heart Association, Inc</publisher><subject>Antihypertensive agents ; Biological and medical sciences ; Cardiovascular system ; Medical sciences ; Pharmacology. Drug treatments</subject><ispartof>Hypertension (Dallas, Tex. 1979), 1998-12, Vol.32 (6), p.989-997</ispartof><rights>1998 American Heart Association, Inc.</rights><rights>1999 INIST-CNRS</rights><rights>Copyright American Heart Association, Inc. Dec 1998</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3737-95ebe80ebd510a4a12c8c2a110b3139b98f6a8b2e568b76dc62e82981f34b5763</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,3674,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1679814$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:1952129$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Dahlof, Bjorn</creatorcontrib><creatorcontrib>Devereux, Richard B</creatorcontrib><creatorcontrib>Julius, Stevo</creatorcontrib><creatorcontrib>Kjeldsen, Sverre E</creatorcontrib><creatorcontrib>Beevers, Gareth</creatorcontrib><creatorcontrib>de Faire, Ulf</creatorcontrib><creatorcontrib>Fyhrquist, Frej</creatorcontrib><creatorcontrib>Hedner, Thomas</creatorcontrib><creatorcontrib>Ibsen, Hans</creatorcontrib><creatorcontrib>Kristianson, Krister</creatorcontrib><creatorcontrib>Lederballe-Pedersen, Ole</creatorcontrib><creatorcontrib>Lindholm, Lars H</creatorcontrib><creatorcontrib>Nieminen, Markku S</creatorcontrib><creatorcontrib>Omvik, Per</creatorcontrib><creatorcontrib>Oparil, Suzanne</creatorcontrib><creatorcontrib>Wedel, Hans</creatorcontrib><title>Characteristics of 9194 Patients With Left Ventricular Hypertrophy: The LIFE Study</title><title>Hypertension (Dallas, Tex. 1979)</title><description>Losartan was the first available orally administered selective antagonist of the angiotensin II type 1 receptor developed for the treatment of hypertension. The Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study is a double-blind, prospective, parallel group study designed to compare the effects of losartan with those of the beta-blocker atenolol on the reduction of cardiovascular morbidity and mortality. Patients with essential hypertension, aged between 55 and 80 years, and ECG-documented left ventricular hypertrophy (LVH) were included. Altogether, 9223 patients in Scandinavia, the United Kingdom, and the United States were randomized from June 1995 through April 1997, and 9194 remain after exclusion of a study center at which irregularities were discovered. This population of hypertensives (mean systolic/diastolic blood pressure, 174.4/97.8 mm Hg) with LVH comprises women (54.1%) and men, mostly retired from active work (mean age, 66.9 years), with a high prevalence of overweight (mean body mass index, 28.0 kg/m), diabetes mellitus (12.3%), lipid disorders (18.0%), and symptoms or signs of coronary heart disease (15.1%). There were fewer current smokers (<17%) than in the general population, and [almost equal to]7% were nonwhite. Almost 30% of participants had been untreated for at least 6 months when screened for the study. Only 1557 persons who entered the placebo run-in period of 14 days were excluded, predominantly because of sitting blood pressures above or below the predetermined range of 160-200/95-115 mm Hg and ECG-LVH criteria not met. By application of simple 12-lead ECG criteria for LVH (Cornell voltage QRS duration product formula plus Sokolow-Lyon voltage read by a core laboratory), hypertensive patients with LVH with an average 5-year coronary heart disease risk of 22.3% according to the Framingham score were identified. This population is now being treated (goal, <140/90 mm Hg) in adherence with the protocol for at least 4 years after final enrollment (ie, through April 2001) and until at least 1040 patients suffer myocardial infarction, stroke, or cardiovascular death. (Hypertension. 1998;32:989-997.)</description><subject>Antihypertensive agents</subject><subject>Biological and medical sciences</subject><subject>Cardiovascular system</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><issn>0194-911X</issn><issn>1524-4563</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><recordid>eNpFkE1r3DAQhkVoIdu051xF6NWORpJlKbewJN3AQkObfuQkZO0YO3HWriSz7L-vll3aucwHz7wzvIRcAisBFFwzKFfPj6XgpSqNNmdkARWXhayUeEcWDIwsDMDvc_IhxhfGQEpZL8i3ZeeC8wlDH1PvIx1bajJLH13qcZsi_dWnjq6xTfRn7kPv58EFutpPGFIYp25_Q586pOuH-zv6Pc2b_UfyvnVDxE-nfEF-3N89LVfF-uuXh-XtuvCiFnVhKmxQM2w2FTAnHXCvPXcArBEgTGN0q5xuOFZKN7XaeMVRc6OhFbKpaiUuSHHUjTuc5sZOoX9zYW9H19vT6DVXaKXgWsjMXx35KYx_ZozJvoxz2OYXLWcV1xVXOkPXR8iHMcaA7T9ZYPbgs2Vgs89WcKts9jlvfD7Juujd0Aa39X38v6bq_PPhujxiu3HIbsfXYd5hsB26IXWW5ZD5fgEm0zx3xWFUi7_CtYu8</recordid><startdate>199812</startdate><enddate>199812</enddate><creator>Dahlof, Bjorn</creator><creator>Devereux, Richard B</creator><creator>Julius, Stevo</creator><creator>Kjeldsen, Sverre E</creator><creator>Beevers, Gareth</creator><creator>de Faire, Ulf</creator><creator>Fyhrquist, Frej</creator><creator>Hedner, Thomas</creator><creator>Ibsen, Hans</creator><creator>Kristianson, Krister</creator><creator>Lederballe-Pedersen, Ole</creator><creator>Lindholm, Lars H</creator><creator>Nieminen, Markku S</creator><creator>Omvik, Per</creator><creator>Oparil, Suzanne</creator><creator>Wedel, Hans</creator><general>American Heart Association, Inc</general><general>Lippincott</general><scope>IQODW</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>ADTPV</scope><scope>AOWAS</scope></search><sort><creationdate>199812</creationdate><title>Characteristics of 9194 Patients With Left Ventricular Hypertrophy: The LIFE Study</title><author>Dahlof, Bjorn ; Devereux, Richard B ; Julius, Stevo ; Kjeldsen, Sverre E ; Beevers, Gareth ; de Faire, Ulf ; Fyhrquist, Frej ; Hedner, Thomas ; Ibsen, Hans ; Kristianson, Krister ; Lederballe-Pedersen, Ole ; Lindholm, Lars H ; Nieminen, Markku S ; Omvik, Per ; Oparil, Suzanne ; Wedel, Hans</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3737-95ebe80ebd510a4a12c8c2a110b3139b98f6a8b2e568b76dc62e82981f34b5763</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Antihypertensive agents</topic><topic>Biological and medical sciences</topic><topic>Cardiovascular system</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dahlof, Bjorn</creatorcontrib><creatorcontrib>Devereux, Richard B</creatorcontrib><creatorcontrib>Julius, Stevo</creatorcontrib><creatorcontrib>Kjeldsen, Sverre E</creatorcontrib><creatorcontrib>Beevers, Gareth</creatorcontrib><creatorcontrib>de Faire, Ulf</creatorcontrib><creatorcontrib>Fyhrquist, Frej</creatorcontrib><creatorcontrib>Hedner, Thomas</creatorcontrib><creatorcontrib>Ibsen, Hans</creatorcontrib><creatorcontrib>Kristianson, Krister</creatorcontrib><creatorcontrib>Lederballe-Pedersen, Ole</creatorcontrib><creatorcontrib>Lindholm, Lars H</creatorcontrib><creatorcontrib>Nieminen, Markku S</creatorcontrib><creatorcontrib>Omvik, Per</creatorcontrib><creatorcontrib>Oparil, Suzanne</creatorcontrib><creatorcontrib>Wedel, Hans</creatorcontrib><collection>Pascal-Francis</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>SwePub</collection><collection>SwePub Articles</collection><jtitle>Hypertension (Dallas, Tex. 1979)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dahlof, Bjorn</au><au>Devereux, Richard B</au><au>Julius, Stevo</au><au>Kjeldsen, Sverre E</au><au>Beevers, Gareth</au><au>de Faire, Ulf</au><au>Fyhrquist, Frej</au><au>Hedner, Thomas</au><au>Ibsen, Hans</au><au>Kristianson, Krister</au><au>Lederballe-Pedersen, Ole</au><au>Lindholm, Lars H</au><au>Nieminen, Markku S</au><au>Omvik, Per</au><au>Oparil, Suzanne</au><au>Wedel, Hans</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Characteristics of 9194 Patients With Left Ventricular Hypertrophy: The LIFE Study</atitle><jtitle>Hypertension (Dallas, Tex. 1979)</jtitle><date>1998-12</date><risdate>1998</risdate><volume>32</volume><issue>6</issue><spage>989</spage><epage>997</epage><pages>989-997</pages><issn>0194-911X</issn><eissn>1524-4563</eissn><coden>HPRTDN</coden><abstract>Losartan was the first available orally administered selective antagonist of the angiotensin II type 1 receptor developed for the treatment of hypertension. The Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study is a double-blind, prospective, parallel group study designed to compare the effects of losartan with those of the beta-blocker atenolol on the reduction of cardiovascular morbidity and mortality. Patients with essential hypertension, aged between 55 and 80 years, and ECG-documented left ventricular hypertrophy (LVH) were included. Altogether, 9223 patients in Scandinavia, the United Kingdom, and the United States were randomized from June 1995 through April 1997, and 9194 remain after exclusion of a study center at which irregularities were discovered. This population of hypertensives (mean systolic/diastolic blood pressure, 174.4/97.8 mm Hg) with LVH comprises women (54.1%) and men, mostly retired from active work (mean age, 66.9 years), with a high prevalence of overweight (mean body mass index, 28.0 kg/m), diabetes mellitus (12.3%), lipid disorders (18.0%), and symptoms or signs of coronary heart disease (15.1%). There were fewer current smokers (<17%) than in the general population, and [almost equal to]7% were nonwhite. Almost 30% of participants had been untreated for at least 6 months when screened for the study. Only 1557 persons who entered the placebo run-in period of 14 days were excluded, predominantly because of sitting blood pressures above or below the predetermined range of 160-200/95-115 mm Hg and ECG-LVH criteria not met. By application of simple 12-lead ECG criteria for LVH (Cornell voltage QRS duration product formula plus Sokolow-Lyon voltage read by a core laboratory), hypertensive patients with LVH with an average 5-year coronary heart disease risk of 22.3% according to the Framingham score were identified. This population is now being treated (goal, <140/90 mm Hg) in adherence with the protocol for at least 4 years after final enrollment (ie, through April 2001) and until at least 1040 patients suffer myocardial infarction, stroke, or cardiovascular death. (Hypertension. 1998;32:989-997.)</abstract><cop>Philadelphia, PA</cop><cop>Hagerstown, MD</cop><pub>American Heart Association, Inc</pub><doi>10.1161/01.HYP.32.6.989</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0194-911X |
| ispartof | Hypertension (Dallas, Tex. 1979), 1998-12, Vol.32 (6), p.989-997 |
| issn | 0194-911X 1524-4563 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_432834 |
| source | EZB Electronic Journals Library; American Heart Association; Journals@Ovid Complete |
| subjects | Antihypertensive agents Biological and medical sciences Cardiovascular system Medical sciences Pharmacology. Drug treatments |
| title | Characteristics of 9194 Patients With Left Ventricular Hypertrophy: The LIFE Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T00%3A53%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Characteristics%20of%209194%20Patients%20With%20Left%20Ventricular%20Hypertrophy:%20The%20LIFE%20Study&rft.jtitle=Hypertension%20(Dallas,%20Tex.%201979)&rft.au=Dahlof,%20Bjorn&rft.date=1998-12&rft.volume=32&rft.issue=6&rft.spage=989&rft.epage=997&rft.pages=989-997&rft.issn=0194-911X&rft.eissn=1524-4563&rft.coden=HPRTDN&rft_id=info:doi/10.1161/01.HYP.32.6.989&rft_dat=%3Cproquest_swepu%3E37618734%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=205285268&rft_id=info:pmid/&rfr_iscdi=true |